IRB #

STUDY00021570

Title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid

Principal Investigator

Teri Greiling

Study Purpose

The main purpose of this study is to investigate whether the study drug, dupilumab, is effective and safe for treatment of bullous pemphigoid.

Medical Condition(s)

bullous pemphigoid, BP

Eligibility Criteria

Below are a list of criteria that would exclude from participating:
1. Forms of pemphigoid other than classic BP
2. Receiving treatments known to cause or exacerbate BP
3. Previous use of the study drug
4. Current diagnosis of hepatitis B or C

Other exclusion criteria will be discussed with the study team later

Healthy Volunteers Needed

No

Placebo Chance

50%

Duration of Participation

approximately 50 weeks

Minors Included

No

Contact

dermtrials@ohsu.edu or call 503-418-9386

Sponsor

Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis US

Recruitment End

12/31/2021

Compensation Provided

No


Go Back